Ravi Chhatrala1, Yasmin Thanavala2, Renuka Iyer3
1Department of Medicine, Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University, Richmond, VA, USA
2Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY, USA
3Department of Medicine, Division of Medical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA
DOI: 10.4103/1477-3163.127639
ABSTRACT
Increased understanding of cancer pathogenesis has identified several pathways that serve as potential targets for novel targeted agents in development. The selection of targeted cancer therapy based on biomarkers has instigated a new era of personalized medicine and changed the way we practice oncology. Many targeted agents are approved for treatment of gastrointestinal malignancies most targeting tumor angiogenesis, and many more are in different phases of development. Here we briefly summarize nine different targeted agents that are approved currently in the U.S. and several other agents currently being studied in various gastrointestinal cancers.
Keywords: Gastrointestinal cancers, monoclonal antibodies, targeted drugs, tyrosine kinase inhibitors